MAPT and Alzheimer disease: Here, we investigated sclerostin's role across the clinical stages of AD.<h4>Methods</h4>We evaluated cerebrospinal fluid (CSF) sclerostin levels in patients with dementia due to AD, mild cognitive impairment, and subjective memory complaints, biologically characterized via the amyloid/tau/neurodegeneration classification.